Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates targeted tumor uptake and blood–brain barrier penetration in glioblastoma mice, highlighting a novel PET tracer for HIF-2α imaging.
High Resolution Image Download MS PowerPoint Slide Hypoxia is a major driver of tumor progression and therapeutic resistance, with hypoxia-inducible factor 2α (HIF-2α) playing a critical regulatory role. To address the current lack of noninvasive imaging tools for HIF-2α, we developed [ 18 F]-TC-S 7009, the F-18 labeled PET tracer designed to target HIF-2α. The probe was synthesized via copper-mediated fluorination, achieving high radiochemical purity and strong binding affinity for HIF-2α ( K d = 81 nM). In vivo PET/CT imaging in U87 glioblastoma-bearing mice demonstrated efficient blood–brain barrier penetration, modest tumor uptake, and favorable tumor-to-background contrast. Blocking experiments confirmed receptor-specific binding. Region-specific brain accumulation was observed in the hippocampus, striatum, and hypothalamus. These findings establish [ 18 F]-TC-S 7009 as a promising noninvasive molecular imaging tool for visualizing HIF-2α activity, providing a foundation for future investigations into hypoxia-driven tumor biology and the development of targeted therapies.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: